What is HC Wainwright’s Estimate for CNTB Q1 Earnings?

Connect Biopharma Holdings Limited (NASDAQ:CNTB) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Connect Biopharma in a note issued to investors on Monday, March 31st. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings per share of ($0.26) for the quarter. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Connect Biopharma’s current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Connect Biopharma’s Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.12) EPS, FY2026 earnings at ($1.32) EPS, FY2027 earnings at ($0.52) EPS, FY2028 earnings at ($0.52) EPS and FY2029 earnings at ($0.22) EPS.

Connect Biopharma Price Performance

NASDAQ CNTB opened at $0.63 on Thursday. Connect Biopharma has a 12 month low of $0.55 and a 12 month high of $2.31. The stock’s 50 day moving average is $0.87 and its 200 day moving average is $1.06.

Hedge Funds Weigh In On Connect Biopharma

Hedge funds and other institutional investors have recently modified their holdings of the stock. Choreo LLC bought a new stake in Connect Biopharma in the 4th quarter valued at $204,000. Callan Capital LLC grew its position in shares of Connect Biopharma by 91.3% during the fourth quarter. Callan Capital LLC now owns 80,000 shares of the company’s stock valued at $110,000 after purchasing an additional 38,177 shares in the last quarter. Finally, Catalina Capital Group LLC bought a new stake in shares of Connect Biopharma in the fourth quarter worth about $66,000. Institutional investors own 58.72% of the company’s stock.

About Connect Biopharma

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.